Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer
Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer
Active, not recruiting · NCT01949662 · Registry updated 2026-07-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer | Chemically-Induced Disorders, Confusion, Hemic and Lymphatic Diseases, Neoplasms by Site, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, cognitive disorder, delirium, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm, nervous system disorder, poisoning, psychiatric disorder, toxic encephalopathy | Active, not recruiting | Phase 2 | 2026-07-17 | NCT01949662 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| M.D. Anderson Cancer Center | 1145 |
| National Cancer Institute (NCI) | 3015 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Texas MD Anderson Cancer Center | Houston | United States | 192 |